top of page
Anchor 1
Test Tubes

Portable Screening Test For Tuberculosis

A Key Requirement To Eradicate a Global Pandemic

Epilab's state of the art technology helps health organisation that want to fight tuberculosis by improving the rate of diagnosis in developing countries and reducing the number of new infections and victims.


Tuberculosis In Figures

10 Million New Cases Each Year

Each year, 10 million people contract tuberculosis. One-third of these new cases, representing about 3 million individuals, are not detected and remain unknown to health organisations. As a result, patients are not receiving appropriate treatment, thereby allowing for ongoing disease transmission.

4 Million Undetected Cases

​Eighty percents of new yearly cases emerge in developing countries that lack resources to implement successful diagnosis campaigns. Existing tests are not adapted to the needs of those countries.

4 in10 people with tuberculosis
are not diagnosed or treated


1.5 Million Victims

Despite being a preventable and curable disease, 1.5 million people die from tuberculosis each year because their diagnosis is “missed,” making it the world’s top infectious disease killer.

The main reason of this underdiagnosis are:

  • Infrastructure (labs) required : most of the population does not have easy access to the few existing infrastructures

  • Medically qualified staff required

  • Testing is expensive.

  • Available tests are unquantifiable and lack sensitivity

epilab screening Test

The answer to underdiagnosis of Tuberculosis in developing countries


No infrastructure needed


Adapted to affected countries

Puce complète sur table milimétrée.jpg

Easy To Use

No qualification needed


Competitive with existing tests

Matches WHO's demand

logo OMS.png
Pipette Inserted Into Test Tube

How We Do It?

We leverage a patented tuberculosis detection method using specific enzymatic reactions coupled with electrochemical detection.

To learn more about EpiLAB patented technology send us a message by clicking the button below.

They Support Us

Get In Touch

Thanks for submitting!

Pipetting Samples



 Rotary Club Impact Startup Award

May 2022

Epilab is honored to receive the Rotary Club Impact StartUp Award. 
This price acknowledges project with a strong social impact while having technological and human dimensions. 


Epilab at ChangeNOW

May 2022

Epilab had the opportunity present the solution for TB detection at ChangeNOW, the world’s largest event for the planet 
Every year, it brings together the most innovative solutions and impactful changemakers tackling our planet’s biggest challenges, to take action, together. ChangeNOW builds bridges between the entrepreneurs, business leaders and policy-makers to accelerate change.


Epilab receives BPI DeepTech label

January 2022

Epilab officially labeled Deeptech by Bpifrance! 
One more step towards the deployment of Epilab portable screening kit.


1M€ seed to develop Epilab kit 

February 2022

Epilab raises €1 million to develop its portable, simple and rapid tuberculosis diagnostic kit. This kit will be the first to answer the international's demand for a such a screening tool, and will be deployed in West Africa. 

france biotech.PNG

Interview with Epilab at France biotech

June 2021

biotech fr.PNG

France Biotech is the French trade association of biotechnology companies. Its primary mission is to support the development of this industry in France.
Epilab was the subject of the 5th episode of its "Pépites Healthtech" series where France Biotech present promising start-ups. 


New scientific publication

September 2022

New publication in Talanta : "Rapid electrochemical detection of Mycobacterium tuberculosis in sputum by measuring Ag85 activity with disposable carbon sensors”.
This article presents the first data Epilab patented technology patients samples from Bichat Hospital. The results are very promising with a specificity of 78% and a sensitivity of 89%.


Thank you to everyone who made this journey possible !

Epilab has closed down

December 2023

Even though a clinical study was validated with Cameroon authorities and scheduled for early 2023, the tuberculosis screening market has changed. Many of the technologies developed to screen for Covid have been redirected to tuberculosis screening, making Epilab technology significantly less competitive.
At the end of 2023, Epilab's intellectual property was therefore transferred to public laboratories and the company was liquidated. 
If you are interested in our story, Epilab's cofounders Maurice and Clément appeared in the podcast "Lets fund out". From the beginning to the end, they share the journey of Epilab and what they have learned. 
Links here : Spotify, Apple PodcastYouTubeDeezer.


December 2023

Prix Galien 2022

October 2022

Epilab is selected for the 2022 PrixGalienUSA in the category "Best Startup in the Medical Technology Industry".
It is an honor for us to be nominated for this award, which recognizes excellence in R&D that has significantly improved the human condition. 
The awards ceremony was held on October 27, 2022, in NYC to celebrate the committed companies creating a healthier future for patients.

bottom of page